Induced pluripotent stem cells from a spinal muscular atrophy patient
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy is one of the most common inherited forms of neurological disease leading to infant mortality. Patients have selective loss of lower motor neurons resulting in muscle weakness, paralysis and often death. Although patient fibroblasts have been used extensively to study spinal muscular atrophy, motor neurons have a unique anatomy and physiology which may underlie their vulnerability to the disease process. Here we report the generation of induced pluripotent stem cells from skin fibroblast samples taken from a child with spinal muscular atrophy. These cells expanded robustly in culture, maintained the disease genotype and generated motor neurons that showed selective deficits compared to those derived from the child's unaffected mother. This is the first study to show that human induced pluripotent stem cells can be used to model the specific pathology seen in a genetically inherited disease. As such, it represents a promising resource to study disease mechanisms, screen new drug compounds and develop new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SMA iPSC-derived motor neurons showed a higher vulnerability with reduced dendritic and axonal length.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Technologies to reprogram adult cells back to a pluripotent state, termed induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Yu et al., 2007), provide an unprecedented platform for studying human genetic disorders (Ebert et al., 2009; Mattis et al., 2015).”
From Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier (2017) · cites this paper as Ebert et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“RNA analysis from SMA iPSC-derived motor neuron demonstrates hyperactivation of the endoplasmic reticulum (ER) stress pathway due to activated unfolded SMN [49].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,151
Pvclust: an R package for assessing the uncertainty in hierarchical clustering
Suzuki, R., & Shimodaira, H. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl117 · Cited by 2,451
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Neuronal specification in the spinal cord: inductive signals and transcriptional codes
Jessell, T. M. (2000) · Nature Reviews Genetics · doi:10.1038/35049541 · Cited by 2,089
Cited by
Items 301–400 of 1,000
Bhinge, A., Namboori, S. C., Bithell, A., Soldati, C., Buckley, N. J., & Stanton, L. W. (2016) · Stem Cells · doi:10.1002/stem.2233 · Cited by 71
Human induced pluripotent stem cells and neurodegenerative disease: prospects for novel therapies
Jung, Y. W., Hysolli, E., Kim, K., Tanaka, Y., & Park, I. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283518226 · Cited by 85
“[14] generated iPSCs from fibroblasts of a SMA patient, using the patient’s unaffected mother as a normal control.”
BackgroundGeneration of pancreatic insulin-producing cells from rhesus monkey induced pluripotent stem cells
Zhu, F., Zhang, P. B., Zhang, D. H., Sui, X. Y., Yin, M., Xiang, T. T., Shi, Y., Ding, M. X., & Deng, H. (2011) · Diabetologia · doi:10.1007/s00125-011-2246-x · Cited by 76
“Disease-specific iPSCs have been established from individual patients [5–9], and differentiation of human iPSCs into lineage-specific cells has been achieved [10–13].”
BackgroundHuman motor neuron generation from embryonic stem cells and induced pluripotent stem cells
Nizzardo, M., Simoné, C., Falcone, M., Locatelli, F., Riboldi, G. M., Comi, G. P., & Corti, S. P. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0463-y · Cited by 78
“For example, two recent studies describe that patient-specific iPSCs can be successfully differentiated into motor neurons from ALS [21] and SMA patients [22] as proof of principle for the utility of this technology.”
BackgroundMethodInfluentialKawagoe, S., Higuchi, T., Otaka, M., Shimada, Y., Kobayashi, H., Ida, H., Ohashi, T., Okano, H. J., Nakanishi, M., & Eto, Y. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.06.003 · Cited by 69
Endless Possibilities: Stem Cells and the Vision for Toxicology Testing in the 21st Century
Chapin, R. E., & Stedman, D. B. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp202 · Cited by 69
“One other useful characteristic of stem cells is that iPS cells generated from humans with specific diseases maintain some of the programming characteristic of that disease (Beqqali et al., 2009; Ebert et al., 2009).”
BackgroundSalvagiotto, G., Burton, S., Daigh, C. A., Rajesh, D., Slukvin, I. I., & Seay, N. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017829 · Cited by 80
“HiPSCs have already been shown to be able to differentiate into various lineages, such as cardiac [40], pancreatic [41], hepatic [42], epithelial [6,43,44], neuronal [45–47], adipose [48], and endothelial and hematopoietic [6,11,49–51].”
BackgroundXu, C.-C., Denton, K. R., Wang, Z.-B., Zhang, X., & Li, X. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.021766 · Cited by 78
“Human models of SMA have been established by generating induced pluripotent stem cells (iPSCs) from individuals with SMA (Chang et al., 2011; Corti et al., 2012; Ebert et al., 2009; Sareen et al., 2012) and knocking down the functional SMN in hESCs (Wang et al.”
Stem Cell Challenges in the Treatment of Neurodegenerative Disease
Feng, Z., & Gao, F. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00239.x · Cited by 77
“Second, it will likely be necessary to understand and correct any intrinsic defects in the patient’s neurons and glia before they can be used to generate iPSCs for cell therapy [30,31].”
Mitochondria: Determinants of Stem Cell Fate?
Parker, G. C., Acsádi, G., & Brenner, C. A. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.1806.edi · Cited by 76
Promising New Sources for Pluripotent Stem Cells
Leeb, C., Jurga, M., McGUCKIN, C. P., Moriggl, R., & Kenner, L. (2009) · Stem Cell Reviews and Reports · doi:10.1007/s12015-009-9102-0 · Cited by 74
Brownjohn, P. W., Smith, J., Portelius, E., Serneels, L., Kvartsberg, H., De Strooper, B., Blennow, K., Zetterberg, H., & Livesey, F. J. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.02.006 · Cited by 65
“…from individuals with genetic forms of disease has been demonstrated in a number of conditions, including motor neurons in spinal muscular atrophy (Ebert et al., 2009), dopaminergic midbrain neurons in Parkinson’s disease (Sanchez-Danes et al., 2012), and cortical neurons in Alzheimer’s disease…”
BackgroundRecent advances in the applications of iPSC technology
Wiegand, C., & Banerjee, I. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.05.011 · Cited by 75
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“Treatment with valproic acid, cyclic tetrapeptide histone deacetylase inhibitors, and thyrotropin-releasing hormone (TRH) analog could enhance SMN protein expression to improve motor neuron defects [50].”
BackgroundEngineering the human pluripotent stem cell microenvironment to direct cell fate
Hazeltine, L. B., Selekman, J. A., & Palecek, S. P. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.03.002 · Cited by 66
“…There is considerable interest in deriving various neural cell types from hPSCs for applications in regenerative therapeutics as well as in vitro disease modeling for neurodegenerative diseases including Parkinson’s disease and spinal muscular atrophy (Ebert et al., 2009, Hwang et al., 2009).”
BackgroundInfluentialPopescu, I. R., Nicaise, C., Liu, S., Bisch, G., Knippenberg, S., Daubie, V., Bohl, D., & Pochet, R. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0042 · Cited by 68
Multipotent skin-derived precursors: from biology to clinical translation
Hunt, D. P. J., Jahoda, C. A. B., & Chandran, S. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.004 · Cited by 72
Huang, J., Zhou, S., Niu, X., Hu, B., Li, Q., Zhang, F., Zhang, X., Cai, X., Lou, Y., Liu, F., et al. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0645-8 · Cited by 65
“For example, this technique has been used to generate motor neurons from iPSCs of a patient with spinal muscular atrophy (SMA) that showed selective deficits compared to those derived from the child’s unaffected mother [6].”
MethodPlastin 3 expression in discordant spinal muscular atrophy (SMA) siblings
Bernal, S., Also‐Rallo, E., Martínez‐Hernández, R., Alías, L., Rodríguez, F. J. Á., Millán, J. M., Hernández-Chico, C., Baiget, M., & Tizzano, E. F. (2011) · Neuromuscular Disorders · doi:10.1016/j.nmd.2011.03.009 · Cited by 65
“The recent availability of induced pluripotent stem cells (iPSCs) generated from skin fibroblasts from SMA patients and their capacity to differentiate to various cell types has led to the availability of SMA motor neurons [19].”
BackgroundModeling Huntington's disease with induced pluripotent stem cells
Kaye, J. A., & Finkbeiner, S. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2013.02.005 · Cited by 65
“Thus, how easily will we be able to capture the phenotypes associated with the initiation of late-onset disease symptoms in a short-term culture? So far, iPSCs that have been generated from patients with various neurodegenerative disorders indeed display robust phenotypes that replicate many features of their respecti…”
Pluripotent stem cell-based disease modeling: current hurdles and future promise
Zeltner, N., & Studer, L. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.008 · Cited by 71
Generating Human Neurons In Vitro and Using Them to Understand Neuropsychiatric Disease
Paşca, S. P., Panagiotakos, G., & Dolmetsch, R. E. (2014) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-062012-170328 · Cited by 64
“One of the earliest examples of in vitro disease modeling investigated spinal muscular atrophy (Ebert et al. 2009).”
BackgroundOrgans to Cells and Cells to Organoids: The Evolution of in vitro Central Nervous System Modelling
Pacitti, D., Privolizzi, R., & Bax, B. E. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00129 · Cited by 72
Morphologic and Gene Expression Criteria for Identifying Human Induced Pluripotent Stem Cells
Wakao, S., Kitada, M., Kuroda, Y., Ogura, F., Murakami, T., Niwa, A., & Dezawa, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048677 · Cited by 64
“Disease-specific iPS cells generated from patients are also expected to be applicable for the evaluation of disease mechanisms and drug efficacy [4,5].”
BackgroundXu, X., & Zhong, Z. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.63 · Cited by 74
PIIKA 2: An Expanded, Web-Based Platform for Analysis of Kinome Microarray Data
Trost, B., Kindrachuk, J., Määttänen, P., Napper, S., & KUSALIK, A. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080837 · Cited by 75
Mechanotransduction: Tuning Stem Cells Fate
D’Angelo, F., Tiribuzi, R., Armentano, I., Kenny, J. M., Martino, S., & Orlacchio, A. (2011) · Journal of Functional Biomaterials · doi:10.3390/jfb2020067 · Cited by 71
“into motorneurons initially, however, these cells degenerate with time, unlike their counterpart derived from the patient‟s healthy mother [89,90].”
BackgroundEnhancing stem cell survival in vivo for tissue repair
Hyun, J. S., Tran, M. C., Wong, V., Chung, M. T., Lo, D. D., Montoro, D. T., Wan, D. C., & Longaker, M. T. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.11.003 · Cited by 66
“Disease-specific iPS cell lines have already been created from patients suffering from amyotrophic lateral sclerosis, juvenile onset type 1 diabetes mellitus, Parkinson's disease, and spinal muscular atrophy (Dimos et al., 2008; Ebert et al., 2009; Park et al., 2008).”
BackgroundMak, S. K., Huang, Y. A., Iranmanesh, S., Vangipuram, M., Sundararajan, R., Nguyen, L., Langston, J. W., & Schüle, B. (2012) · Stem Cells International · doi:10.1155/2012/140427 · Cited by 71
“In particular for monogenic forms of disease, patient-derived iPSCs have already been shown to recapitulate known disease mechanisms, as shown in spinal muscular atrophy [4], fragile X syndrome [5], progeria syndrome [6], and several genetic forms of Parkinson disease (PD) like LRRK2 [7], PINK1 [8], SNCA [9], and GBA…”
BackgroundStem cell culture engineering – process scale up and beyond
Sharma, S., Raju, R., Sui, S., & Hu, W. (2011) · Biotechnology Journal · doi:10.1002/biot.201000435 · Cited by 71
“Recently iPSCs from patients with familial dysautonomia (FD) and spinal muscular atrophy (SMA) have been employed in developing disease models [29, 30].”
MethodHamasaki, M., Hashizume, Y., Yamada, Y., Katayama, T., Hohjoh, H., Fusaki, N., Nakashima, Y., Furuya, H., Haga, N., Takami, Y., et al. (2012) · Stem Cells · doi:10.1002/stem.1221 · Cited by 66
A practical guide to induced pluripotent stem cell research using patient samples
Santostefano, K. E., Hamazaki, T., Biel, N. M., Jin, S., Umezawa, A., & Terada, N. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.104 · Cited by 66
Human pluripotent stem cells for disease modelling and drug screening
Maury, Y., Gauthier, M., Peschanski, M., & Martinat, C. (2011) · BioEssays · doi:10.1002/bies.201100071 · Cited by 76
A Cyclic AMP Analog, 8-Br-cAMP, Enhances the Induction of Pluripotency in Human Fibroblast Cells
Wang, Y., & Adjaye, J. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9209-3 · Cited by 69
Induced pluripotent stem cells: what lies beyond the paradigm shift
Cox, J. L., & Rizzino, A. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2009.009267 · Cited by 69
Thatava, T., Armstrong, A. S., Lamo, J. G. D., Edukulla, R., Khan, Y. K., Sakuma, T., Ohmine, S., Sundsbak, J. L., Harris, P. C., Kudva, Y. C., et al. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt89 · Cited by 66
“Although autologous iPS cells have been generated from patients with various diseases/disorders [17-23], the feasibility and reproducibility of iPS cell derivation from kidney diseases, such as ADPKD, has remained elusive.”
BackgroundLi, Y., Cao, J., Chen, M., Li, J., Sun, Y., Zhang, Y., Zhu, Y., Wang, L., & Zhang, C. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.02.020 · Cited by 62
“Patient-specific induced pluripotent stem cells (iPSCs), which can model the pathology of a specific disease, represent a promising resource for studying disease mechanisms, screening for novel drug compounds, and developing new therapies (Ebert et al., 2009).”
BackgroundInduced Pluripotent Stem Cells: Next Generation Cells for Tissue Regeneration
Ibrahim, A. Y., Mehdi, M. Q., Abbas, A. O., Alashkar, A. H., & Haider, K. H. (2016) · Journal of Biomedical Science and Engineering · doi:10.4236/jbise.2016.94017 · Cited by 61
Modeling Alzheimer’s disease: from past to future
Saraceno, C., Musardo, S., Marcello, E. E., Pelucchi, S., & Luca, M. D. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00077 · Cited by 75
“…diseases, and some of them have demonstrated disease-specific phenotypes to model the neurological phenotype (Dimos et al., 2008; Park et al., 2008; Ebert et al., 2009; Lee et al., 2009; Soldner et al., 2009; Chamberlain et al., 2010; Ku et al., 2010; Marchetto et al., 2010; Nguyen et al., 2011).”
BackgroundElongator – an emerging role in neurological disorders
Nguyen, L., Humbert, S., Saudou, F., & Chariot, A. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.11.002 · Cited by 69
The Pharmacology of Regenerative Medicine
Christ, G. J., Saul, J. M., Furth, M. E., & Andersson, K. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007393 · Cited by 65
“A first example came from the identification of motor neuron abnormalities in neural-lineage cells differentiated in vitro from patient-specific iPS cells for human spinal muscular atrophy, an autosomal recessive genetic disorder resulting from mutations that decrease levels of the protein survival motor neuron 1 (Ebe…”
BackgroundUsing iPS Cells toward the Understanding of Parkinson’s Disease
Torrent, R., De Angelis Rigotti, F., Dell'Era, P., Memo, M., Raya, A., & Consiglio, A. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4040548 · Cited by 60
“diseases [17–24].”
Human Pluripotent Stem Cells for Modelling Human Liver Diseases and Cell Therapy
Dianat, N., Steichen, C., Vallier, L., Weber, A., & Dubart-Kupperschmitt, A. (2013) · Current Gene Therapy · doi:10.2174/1566523211313020006 · Cited by 59
“These iPSCs were differentiated into motor neurons, which displayed selective deficits with respect to motor neurons generated from an individual not affected by spinal muscular atrophy [72, 73].”
Spinal muscular atrophy patient-derived motor neurons exhibit hyperexcitability
Liu, H., Lü, J., Chen, H., Du, Z., Li, X.-J., & Zhang, S. (2015) · Scientific Reports · doi:10.1038/srep12189 · Cited by 67
Garcia, V. J., Rushton, D. J., Tom, C. M., Allen, N. D., Kemp, P. J., Svendsen, C. N., & Mattis, V. B. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00669 · Cited by 62
Self-citationQiang, L., Fujita, R., & Abeliovich, A. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.002 · Cited by 59
Induced Pluripotent Stem Cell Technology in Regenerative Medicine and Biology
Pei, D., Xu, J., Zhuang, Q., Tse, H., & Esteban, M. A. (2010) · Springer eBooks · doi:10.1007/10_2010_72 · Cited by 67
Progress and Promise Towards Safe Induced Pluripotent Stem Cells for Therapy
Seifinejad, A., Tabebordbar, M., Baharvand, H., Boyer, L. A., & Salekdeh, G. H. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9121-x · Cited by 65
“For instance, iPSCs derived from the skin fibroblasts of a child with Spinal Muscular Atrophy (SMA) (an early onset disease) exhibited the disease phenotype and generated motor neurons that showed selective deficits compared to those generated from the unaffected mother [ 21 ].”
BackgroundImmunohistochemical Toolkit for Tracking and Quantifying Xenotransplanted Human Stem Cells
Allard, J., Li, K., Lopez, X. M., Blanchard, S., Barbot, P., Rorive, S., Decaestecker, C., Pochet, R., Bohl, D., Lepore, A. C., et al. (2014) · Regenerative Medicine · doi:10.2217/rme.14.26 · Cited by 62
Liu, T., Zou, G., Gao, Y., Zhao, X., Wang, H., Huang, Q. M., Jiang, L., Guo, L., & Cheng, W. (2012) · Stem Cells and Development · doi:10.1089/scd.2011.0715 · Cited by 63
Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine
Oh, Y., Wei, H., Ma, D., Sun, X., & Liew, R. (2012) · Heart · doi:10.1136/heartjnl-2011-301317 · Cited by 64
Corti, S. P., Faravelli, I., Cardano, M., & Conti, L. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1037737 · Cited by 67
“(2009) [12] hiPSC line from a SMA I patient Motor neurons SMN mutation affected late phases of MN maturation rather than early development Sareen et al.”
BackgroundInfluentialThe Molecular Mechanism of Induced Pluripotency: A Two-Stage Switch
Scheper, W., & Copray, S. C. V. M. (2009) · Stem Cell Reviews and Reports · doi:10.1007/s12015-009-9077-x · Cited by 67
“iPS cells obtained from amyotrophic lateral sclerosis [15] and from spinal muscular atrophy [27] patients could be terminally differentiated into motor neurons.”
BackgroundResultHuman induced pluripotent stem cells—from mechanisms to clinical applications
Drews, K., Józefczuk, J., Prigione, A., & Adjaye, J. (2012) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0913-0 · Cited by 71
“Spinal muscular atrophy (SMA) [80] Mutations in SMN1 Astrocytes, neurons, mature motor neurons Yes Tobramycin and VPA”
Nizzardo, M., Simone, C., Rizzo, F., Salani, S., Dametti, S., Rinchetti, P., Del Bo, R., Foust, K., Kaspar, B. K., Bresolin, N., et al. (2015) · Science Advances · doi:10.1126/sciadv.1500078 · Cited by 58
Piras, A., Schiaffino, L., Boido, M., Valsecchi, V., Guglielmotto, M., Amicis, E. D., Puyal, J., Garcerá, A., Tamagno, E., Soler, R. M., et al. (2017) · Cell Death and Disease · doi:10.1038/s41419-017-0086-4 · Cited by 67
Matrix stiffness modulates the differentiation of neural crest stem cells in vivo
Zhu, Y., Li, X., Janairo, R. R. R., Kwong, G., Tsou, A. D., Chu, J. S. F., Wang, A., Yu, J. L., Wang, D., & Li, S. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27518 · Cited by 61
“iPSC provides an unlimited cell source for the derivation of various cell types for the applications such as regenerative medicine and disease modeling (Ebert et al., 2009; Hirschi, Li, & Roy, 2014; Lian et al., 2010; Park et al., 2008).”
Self-citationEpileptogenic ion channel mutations: From bedside to bench and, hopefully, back again
Mantegazza, M., Rusconi, R., Scalmani, P., AVANZINI, G., & Franceschetti, S. (2010) · Epilepsy Research · doi:10.1016/j.eplepsyres.2010.08.003 · Cited by 61
“…abnormalities typical f SMA motor neurons were observed in the cells derived rom the SMA patient and not in those derived from the naffected mother (Ebert et al., 2009), but in these studes the neurons obtained re-differentiating iPS cells have een characterized merely by studying the expression…”
Targeting SR Proteins Improves SMN Expression in Spinal Muscular Atrophy Cells
Wee, C. D., Havens, M. A., Jodelka, F. M., & Hastings, M. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115205 · Cited by 61
“We next tested the effect of knockdown of the most effective inhibitor of exon 7 inclusion, SRSF3, in multipotent neural stem cells generated from iPS cells derived from a type 1 SMA patient [48, 57, 58].”
BackgroundMethodGeneration of Human-Induced Pluripotent Stem Cells to Model Spinocerebellar Ataxia Type 2 In vitro
Xia, G., Santostefano, K. E., Hamazaki, T., Liu, J., Subramony, S. H., Terada, N., & Ashizawa, T. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9930-2 · Cited by 64
“In these studies, iPS cells recapitulated some disease features and showed potential to become a platform for drug development (Ebert et al. 2009; Lee and Studer 2011).”
BackgroundInfluentialWang, Z.-B., Zhang, X., & Li, X.-J. (2012) · Cell Research · doi:10.1038/cr.2012.166 · Cited by 64
Human Cytomegalovirus Disruption of Calcium Signaling in Neural Progenitor Cells and Organoids
Sison, S. L., O’Brien, B. S., Johnson, A. J., Seminary, E. R., Terhune, S. S., & Ebert, A. D. (2019) · Journal of Virology · doi:10.1128/jvi.00954-19 · Cited by 62
Self-citationGeneration of Healthy Mice from Gene-Corrected Disease-Specific Induced Pluripotent Stem Cells
Wu, G., Liu, N., Rittelmeyer, I., Sharma, A. D., Sgodda, M., Zaehres, H., Bleidißel, M., Greber, B., Gentile, L., Han, D., et al. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001099 · Cited by 61
“Various human disease-specific iPS cell lines have been generated [6] either for disease modeling [7–16] or for cell transplantation in”
BackgroundNonxenogeneic Growth and Retinal Differentiation of Human Induced Pluripotent Stem Cells
Sridhar, A., Steward, M., & Meyer, J. S. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0101 · Cited by 61
Sheng, X., Reppel, M., Nguemo, F., Mohammad, F. I., Kuzmenkin, A., Hescheler, J., & Pfannkuche, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045963 · Cited by 56
“In addition, several patient-specific induced pluripotent stem cell lines for cardiovascular disease, neurodegenerative and metabolic disorders have been developed [23–28].”
BackgroundT lineage differentiation from induced pluripotent stem cells
Lei, F., Haque, R., Kaminsky, L. W., Vrana, K. E., & Song, J. J. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.09.005 · Cited by 62
Neural stem cells: mechanisms and modeling
Yao, J., Mu, Y., & Gage, F. H. (2012) · Protein & Cell · doi:10.1007/s13238-012-2033-6 · Cited by 71
“…lateral sclerosis (ALS), PD (Dimos et al., 2008; Park et al., 2008; Soldner et al., 2009), spinal muscular atrophy (SMA), familial dysautonomia (FD) (Ebert et al., 2009; © Higher Education Press and Springer-Verlag Berlin Heidelberg 2012 255 Lee et al., 2009), and AD (Israel et al., 2012).”
BackgroundConcise Review: Patient-Derived Olfactory Stem Cells: New Models for Brain Diseases
Mackay‐Sim, A. (2012) · Stem Cells · doi:10.1002/stem.1220 · Cited by 64
Bioreactor engineering of stem cell environments
Tandon, N. M., Marolt, D., Cimetta, E., & Vunjak‐Novakovic, G. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.03.007 · Cited by 66
“A series of diseases have already been successfully modeled in vitro via reprogramming of patient cells to iPS cells followed by differentiation into disease-relevant cells and tissues: neurodegenerative diseases, haematopoietic disorders, metabolic conditions and cardiovascular pathologies (Chamberlain et al. 2008; E…”
BackgroundAlzheimer's disease in a dish: promises and challenges of human stem cell models
Young, J. E., & Goldstein, L. S. B. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds319 · Cited by 57
“These disorders include Parkinson’s disease (PD) (26–29), amyotrophic lateral sclerosis (30,31), smooth muscle atrophy (32) and familial dysautonomia (33), and this work has been recently reviewed (34).”
BackgroundBack and forth in time: Directing age in iPSC-derived lineages
Cornacchia, D., & Studer, L. (2017) · Brain Research · doi:10.1016/j.brainres.2015.11.013 · Cited by 56
Tumorigenic and Immunogenic Properties of Induced Pluripotent Stem Cells: a Promising Cancer Vaccine
Qiao, Y., Agboola, O. S., Hu, X., Wu, Y., & Lei, L. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10042-5 · Cited by 64
Stem cells as a potential therapy for epilepsy
Roper, S. N., & Steindler, D. A. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.004 · Cited by 59
“A flurry of publications have appeared since these first papers describing the utilization of iPSC technology for a variety of devastating human diseases, including other neurodegenerative diseases such as spinal muscular atrophy (Ebert et al., 2009) and Parkinson's disease (Park et al.”
BackgroundBoué, S., Paramonov, I., Barrero, M. J., & Belmonte, J. C. I. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012664 · Cited by 62
“Briefly, cornerstone publications in the reprogramming field have described the following attributes of iPSCs: they can be transmitted to the germ line [2], generated without the oncogenic factor c-Myc [3,4], obtained from human cells using the same set of factors [5,6] as well as other factors [7], obtained without p…”
InfluentialConcise Review: Human Pluripotent Stem Cells in the Treatment of Spinal Cord Injury
Lukovic, D., Moreno‐Manzano, V., Stojković, M., Bhattacharya, S. S., & Erceg, S. (2012) · Stem Cells · doi:10.1002/stem.1159 · Cited by 61
Lian, Q., Chow, Y., Esteban, M., Pei, D., & Tse, H.-F. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-05-0269 · Cited by 55
“(17) reported the successful generation of iPS cells from a child with a genetic form of spinal muscular atrophy.”
BackgroundGeneration of Induced Pluripotent Stem Cells with CytoTune, a Non-Integrating Sendai Virus
Lieu, P. T., Fontes, A., Vemuri, M. C., & MacArthur, C. C. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-348-0_5 · Cited by 56
Safeguarding Nonhuman Primate iPS Cells With Suicide Genes
Zhong, B., Watts, K. L., Gori, J. L., Wohlfahrt, M. E., Enssle, J., Adair, J. E., & Kiem, H. (2011) · Molecular Therapy · doi:10.1038/mt.2011.51 · Cited by 59
Genomic Editing Tools to Model Human Diseases with Isogenic Pluripotent Stem Cells
Kim, H. S., Bernitz, J. M., Lee, D., & Lemischka, I. R. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0167 · Cited by 61
“3 cardiomyocytes with increased depolarization and reduced potassium current, and spinal muscular atrophy iPSCs with SMN1 mutations generate fewer numbers of motor neurons with degenerated and diffuse synapses [18,19,20].”
BackgroundResearch Advances in Amyotrophic Lateral Sclerosis, 2009 to 2010
Traub, R., Mitsumoto, H., & Rowland, L. P. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0160-0 · Cited by 55
Mou, X., Wu, Y., Cao, H., Meng, Q., Wang, Q., Sun, C., Hu, S., Ma, Y., & Zhang, H. (2012) · Stem Cell Research & Therapy · doi:10.1186/scrt105 · Cited by 54
“Recent studies showed that a variety of disease-specific iPSCs may be successfully produced [15-22].”
BackgroundGASPARD, N., & VANDERHAEGHEN, P. (2011) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2010.03827.x · Cited by 54
“Cholinergic motor neurons derived from the SMA iPS cell line exhibited a selective survival deficit which could be reversed by small chemical compounds known to raise the level of the protein encoded by the gene mutated in SMA.(34) A study of the dysautonomia cell line by Lee et al.”
BackgroundUsing stem cell–derived neurons in drug screening for neurological diseases
Little, D., Ketteler, R., Gissen, P., & Devine, M. J. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.008 · Cited by 60
Kidney organoids in translational medicine: Disease modeling and regenerative medicine
Miyoshi, T., Hiratsuka, K., Saiz, E. G., & Morizane, R. (2019) · Developmental Dynamics · doi:10.1002/dvdy.22 · Cited by 60
Onorati, M., Camnasio, S., Binetti, M., Jung, C. B., Moretti, A., & Cattaneo, E. F. (2009) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2009.12.002 · Cited by 58
“Furthermore, two studies described the characterization of iPS cells derived from patients with a neurodegenerative disease, thus validating iPS cells as a potential in vitro model of human diseases (Dimos et al., 2008; Ebert et al., 2009).”
BackgroundSalewski, R. P., Eftekharpour, E., & Fehlings, M. G. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21995 · Cited by 56
“Although the iPS cells retained a SMA1 genotype, they grew robustly in culture and were directed toward a NPC phenotype under minimal condition. iPS cell-derived NPCs generated neuronal and glial cells.”
BackgroundInfluentialStem cell-derived motor neurons from spinal and bulbar muscular atrophy patients
Grunseich, C., Zukosky, K., Kats, I. R., Ghosh, L., Harmison, G. G., Bott, L. C., Rinaldi, C., Chen, K., Chen, G., Boehm, M., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.038 · Cited by 54
“Available online on ScienceDirect (www.sciencedir 1 These authors contributed equally to this work. http://dx.doi.org/10.1016/j.nbd.2014.05.038 0969-9961/Published by Elsevier Inc. a b s t r a c t a r t i c l e i n f o”
BackgroundInfluentialAdult human brain cell culture for neuroscience research
Gibbons, H. M., & Dragunow, M. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.12.002 · Cited by 59
Natarajan, A., Sethumadhavan, A., & Krishnan, U. M. (2019) · ACS Omega · doi:10.1021/acsomega.9b00973 · Cited by 57
Raya, Á., Rodríguez-Pizà, I., Navarro, S., Richaud‐Patín, Y., Güenechea, G., Sánchez‐Danés, A., Consiglio, A., Bueren, J. A., & Belmonte, J. C. I. (2010) · Nature Protocols · doi:10.1038/nprot.2010.9 · Cited by 60
“has enabled the derivation of disease-specific pluripotent cells and provided valuable experimental platforms to model human diseas”
BackgroundPatani, R., Lewis, P. A., Trabzuni, D., Puddifoot, C. A., Wyllie, D. J. A., Walker, R., Smith, C., Hardingham, G. E., Weale, M., Hardy, J., et al. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07825.x · Cited by 50
Nihei, Y., Ito, D., Okada, Y., Akamatsu, W., Yagi, T., Yoshizaki, T., Okano, H., & Suzuki, N. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.408211 · Cited by 51
“In recent 145 years, patient-derived iPSCs have been used to 146 recapitulate the phenotypes of a number of 147 neurological diseases, thereby broadening our 148 understanding of the pathogenesis of many 149 neurological diseases, including those of late onset 150 (16-27).”
MethodInduced pluripotent stem cell technology for the study of human disease
Lee, G., & Studer, L. (2009) · Nature Methods · doi:10.1038/nmeth.f.283 · Cited by 53
Pluripotent stem cell applications for regenerative medicine
Angelos, M. G., & Kaufman, D. S. (2015) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000244 · Cited by 58
VPA response in SMA is suppressed by the fatty acid translocase CD36
Garbes, L., Heesen, L., Hölker, I., Bauer, T., Schreml, J., Zimmermann, K., Thoenes, M., Walter, M. J., Dimos, J. T., Peitz, M., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds437 · Cited by 55
“During the past years, iPS cells generated from fibroblasts have emerged as a versatile source of diverse cell types—among them CNS neurons (37,38).”
Zibara, K., Ballout, N., Mondello, S., Karnib, N., Ramadan, N., Omais, S., Nabbouh, A. I., Caliz, D., Clavijo, A., Hu, Z., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.032 · Cited by 52
“, 2009), motor neurons (Dimos et al., 2008; Ebert et al., 2008), retinal cells (Osakada et al.”
Baker, M. (2009) · Nature · doi:10.1038/458962a · Cited by 57
Merits and challenges of iPSC-derived organoids for clinical applications
Xu, Z., Yang, J., Xin, X., Liu, C., Li, L., Mei, X., & Li, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1188905 · Cited by 64
“, 2011); iPSCs derived from patients with spinal muscular atrophy could not differentiate into normal motor neurons (Ebert et al., 2009); and cardiomyocytes derived from patients with familial long-QT syndrome had prolonged action potentials similar to those in diseased types (Moretti et al.”
BackgroundIntroduction to Induced Pluripotent Stem Cells: Advancing the Potential for Personalized Medicine
Ebben, J. D., Zorniak, M., Clark, P. A., & Kuo, J. S. (2011) · World Neurosurgery · doi:10.1016/j.wneu.2010.12.055 · Cited by 61
Clinical Therapy Using iPSCs: Hopes and Challenges
Lu, X., & Zhao, T. (2013) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2013.09.002 · Cited by 60
“Spinal muscular atrophy was the first neurological disease targeted in a human iPSC-based study of pathogenesis [15].”
Background
Metadata
- Authors
- Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Missouri (US)
- Corresponding author
- Ebert, Allison D.
- Svendsen, Clive N.
- Venue
- Nature
- Published
- 2008-12-21
- Volume
- 457
- Issue
- 7227
- Pages
- 277-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2659408
- OpenAlex
- W2145492799
- Cited by
- 1,441
- References
- 42
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 28 · 2023: 31 · 2022: 36 · 2021: 33 · 2020: 46 · 2019: 54 · 2018: 53 · 2017: 60 · 2016: 85 · 2015: 109 · 2014: 112 · 2013: 145 · 2012: 199
- FWCI
- 58.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (T32AG027566)
- National Institute of General Medical Sciences (T32GM008396)
- National Institute of Neurological Disorders and Stroke (R01 NS41584, P01NS057778, R01NS041584)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD054413)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, induced pluripotent stem cells, motor neurons, SMN1, SMN2, dermal fibroblasts, disease modeling, neural progenitor cells, drug screening, inherited neurological diseases, Huntington's disease
- MeSH terms
- Cell Differentiation, Cell Separation, Cells, Cultured, Child, Female, Fibroblasts, Gene Expression Regulation, Humans, Male, Models, Biological, Motor Neurons, Muscular Atrophy, Spinal, Skin, Cell Lineage, Pluripotent Stem Cells, Survival of Motor Neuron 1 Protein, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.